Literature DB >> 26176864

A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma.

Tejaswi V Mudigonda1, Kenneth Wyman1, David R Spigel2, Kimberly B Dahlman3, F Anthony Greco2, Igor Puzanov1, Mark C Kelley4, John D Hainsworth2, Jeffrey A Sosman1, Douglas B Johnson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26176864     DOI： 10.1111/pcmr.12394

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


× No keyword cloud information.
  3 in total

Review 1.  Searching for the Chokehold of NRAS Mutant Melanoma.

Authors:  Christian Posch; Igor Vujic; Babak Monshi; Martina Sanlorenzo; Felix Weihsengruber; Klemens Rappersberger; Susana Ortiz-Urda
Journal:  J Invest Dermatol       Date:  2016-05-07       Impact factor: 8.551

Review 2.  Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date.

Authors:  Amélie Boespflug; Julie Caramel; Stephane Dalle; Luc Thomas
Journal:  Ther Adv Med Oncol       Date:  2017-05-29       Impact factor: 8.168

Review 3.  Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other?

Authors:  Irati Beltrán Hernández; Jannes Z Kromhout; Erik Teske; Wim E Hennink; Sebastiaan A van Nimwegen; Sabrina Oliveira
Journal:  Theranostics       Date:  2021-02-06       Impact factor: 11.556
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.